您的购物车当前为空
别名 SERPINA3, serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 3, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3, MGC88254, GIG25, GIG24, ACT, AACT
SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a plasma alpha globulin glycoprotein, and is a member of serpin superfamily of the serine protease inhibitors consisting of at least 35 members. SerpinA3 has been demonstrated to inhibit the activity of certain serine proteases, such as cathepsin G found in neutrophils, and chymases present in mast cells, by inducing a major conformational rearrangement, and thus protects some tissues from damage caused by proteolytic enzymes. This enzyme is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease, and mutations of this gene have been observed in patients with Parkinson disease and chronic obstructive pulmonary disease. Besides, ACT gene polymorphism has been implicated with Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), as well as stroke, since SerpinA3 is a major constituent of the plaques in AD and an inhibitor of amyloid beta peptide degradation.


为众多的药物研发团队赋能,
让新药发现更简单!
SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a plasma alpha globulin glycoprotein, and is a member of serpin superfamily of the serine protease inhibitors consisting of at least 35 members. SerpinA3 has been demonstrated to inhibit the activity of certain serine proteases, such as cathepsin G found in neutrophils, and chymases present in mast cells, by inducing a major conformational rearrangement, and thus protects some tissues from damage caused by proteolytic enzymes. This enzyme is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease, and mutations of this gene have been observed in patients with Parkinson disease and chronic obstructive pulmonary disease. Besides, ACT gene polymorphism has been implicated with Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), as well as stroke, since SerpinA3 is a major constituent of the plaques in AD and an inhibitor of amyloid beta peptide degradation.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 μg | ¥ 987 | 6-8日内发货 | |
| 10 μg | ¥ 1,730 | 6-8日内发货 | |
| 20 μg | ¥ 2,890 | 5日内发货 | |
| 50 μg | ¥ 5,820 | 5日内发货 | |
| 100 μg | ¥ 9,870 | 5日内发货 |
| 产品描述 | SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a plasma alpha globulin glycoprotein, and is a member of serpin superfamily of the serine protease inhibitors consisting of at least 35 members. SerpinA3 has been demonstrated to inhibit the activity of certain serine proteases, such as cathepsin G found in neutrophils, and chymases present in mast cells, by inducing a major conformational rearrangement, and thus protects some tissues from damage caused by proteolytic enzymes. This enzyme is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease, and mutations of this gene have been observed in patients with Parkinson disease and chronic obstructive pulmonary disease. Besides, ACT gene polymorphism has been implicated with Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), as well as stroke, since SerpinA3 is a major constituent of the plaques in AD and an inhibitor of amyloid beta peptide degradation. |
| 生物活性 | Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2. The IC50 value is < 5 nM. |
| 研究背景 | SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a plasma alpha globulin glycoprotein, and is a member of serpin superfamily of the serine protease inhibitors consisting of at least 35 members. SerpinA3 has been demonstrated to inhibit the activity of certain serine proteases, such as cathepsin G found in neutrophils, and chymases present in mast cells, by inducing a major conformational rearrangement, and thus protects some tissues from damage caused by proteolytic enzymes. This enzyme is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease, and mutations of this gene have been observed in patients with Parkinson disease and chronic obstructive pulmonary disease. Besides, ACT gene polymorphism has been implicated with Alzheimer’s disease (AD), cerebral amyloid angiopathy (CAA), as well as stroke, since SerpinA3 is a major constituent of the plaques in AD and an inhibitor of amyloid beta peptide degradation. |
| 种属 | Human |
| 表达系统 | HEK293 Cells |
| 标签 | C-His |
| 蛋白编号 | P01011 |
| 蛋白构建 | A DNA sequence encoding the human SERPINA3 (NP_001076.2) (Met 1-Ala 423) was expressed, with a C-terminal polyhistidine tag. Predicted N terminal: Asn 26 |
| 蛋白纯度 | > 97 % as determined by SDS-PAGE |
| 蛋白性状 | Lyophilized powder |
| 缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing 25 mM HEPES, 0.15M NaCl, pH 7.8. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
| 复溶方法 | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
| 别名 | SERPINA3, serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 3, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3, MGC88254, GIG25, GIG24, ACT, AACT |
| 内毒素 | < 1.0 EU/μg of the protein as determined by the LAL method. |
| 分子量 | 46.5 kDa (predicted); 45 kDa and 55-70 kDa (reducing condition, due to glycosylation) |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. |
| 存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
对于不同动物的给药剂量换算,您也可以参考 更多